Aclaris Therapeutics Forecast and Stock Analysis
Technical ACRS stock analysis for Friday May 24, 2019.
|Price to book||USD 1.15|
|Next Earnings Date||2019-08-04|
No changes to the price of Aclaris Therapeutics in the last trading day ( Friday, 24th May 2019 ). During day the stock fluctuated 0.00% from a day low at $5.03 to a day high of $5.03. The price has fallen in 6 of the last 10 days and is down by -16.03% for this period.
- 30 day high of the ACRS stock price was $7.15 and low was $4.73.
- 90 day high was $7.51 and low was $4.73.
- 52 week high for the Aclaris Therapeutics - $21.97 and low - $4.73.
Aclaris Therapeutics lies in the lower of a very wide and falling trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at $4.94 will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -8.25% during the next 3 months and, with 90% probability hold a price between $4.53 and $6.30 at the end of this period.
There are mixed signals in the stock today. Aclaris Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $5.31 and $5.99. A break-up above any of these levels will issue buy signals. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued. A buy signal was issued from a pivot bottom point on Thursday May 23, 2019, which indicates further gains until a new top pivot has been found.
Relative Strength Index (RSI)
RSI14 is 14 and the stock is currently not being overbought or oversold
Support & Resistance
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.00 between high and low, or 0.00%. For the last week the stock has had a daily average volatility of 6.54%.
Aclaris Therapeutics is overbought on RSI14 (14). Some stocks may go long and hard while being overbought on RSI, but overbought increases the general risk as higher volatility could be expected, and at some level the stock will have a reaction back to gain new strength.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
6.54 %Average volatility
Very Low Low Medium High Very High
Aclaris Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Sell Candidate.
|Golden Star Signal|
Get competitive edge
The signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives a very good return. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!
Get access to Golden Star list now
|ACRS $5.03 ($0.00 0.00%)|
ACRS is down $0.00 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month system that more than doubles the S&P 500.
This report is free today for StockInvest.us readers.
Click here – the ACRS analysis is free »
From Our Blog
- Trading With Moving Average
- Pivot Points
- Accumulated Volume - Support and Resistance
- Volume - The Indicator You Really Need to Know
- We Give Back!
- Better Buy: Amazon vs. Facebook
- Better Buy: Apple vs. Microsoft
- Relative Strength Index (RSI)
- How to Lose Money When Trading: Part 2
- How to Lose Money When Trading: A Trader is Born
- Our 2017 Christmas Donation
- The Golden Star
- Announcing Partnership With CityFALCON
- Why correct moving average matters
- NASDAQ down -4.17%. Our portfolio is up +8.56%
- New Feature Added: Golden Star Signal
- Pick a Winner With StockInvest.us